The Story of Influenza Antivirals: Part 11

The Oxford Meeting: September 2010

The meeting started with a two-hour presentation on the Relenza FDA material (this will summarised in the next instalment). Although some members were badly jet-lagged, the reality and impact of the content of the files dawned on the group.

Over the following two days, we discussed how to tackle a review of unpublished material, in effect creating an ent…